Axsome Therapeutics (AXSM) Operating Leases (2020 - 2026)

Axsome Therapeutics has reported Operating Leases for 6 years, with the latest figure at $22.4 million in Q1 2026.

• Quarterly Operating Leases fell 6.36% year-over-year to $22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.4 million (down 6.36% YoY) and the FY2025 annual result came in at $23.2 million, up 283.43% from the prior year.
• Operating Leases fell to $22.4 million in Q1 2026 per AXSM's latest filing, from $23.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $23.9 million in Q1 2025 and troughed at $6.0 million in Q4 2024.
• A 4-year average of $13.7 million and a median of $7.6 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases retreated 16.27% in 2024, then surged 283.43% in 2025.
• Over 4 years, Operating Leases stood at $7.0 million in 2023, then declined by 14.06% to $6.0 million in 2024, then soared by 283.43% to $23.2 million in 2025, then fell by 3.44% to $22.4 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $22.4 million, $23.2 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.